01.02.2012 18:05 Uhr, Quelle: Wallstreet online
ABLYNX RECEIVES ANOTHER MILESTONE AS BOEHRINGER INGELHEIM SELECTS NANOBODY CANDIDATE FOR PRE-CLINICAL DEVELOPMENT
GHENT, Belgium, 1 February 2012 - Ablynx [Euronext Brussels: ABLX] today announced that Boehringer Ingelheim has selected, as part of their strategic alliance, a second Nanobody(®) candidate for pre-clinical development, which triggered a EUR5 …
Weiterlesen bei Wallstreet online
JustMac.info